Scholarlink

<p>Ten-eleven translocase (<i>TET</i>) enzymes are responsible for DNA demethylation reactions and play a key role in regulating the methylation balance in the body. <i>TET</i> expression instability may result in methylation alterations. We performed methylation specific-polymerase chain reaction to evaluate the <i>TET3</i> promoter hypermethylation in the DNA isolated from the venous blood samples of head and carcinoma (H&amp;NC) cases before initiation of treatment (n = 32) and after treatment (n = 30) and healthy controls (n = 32) in this study. <i>TET3</i> promoter was found to be hypermethylated in H&amp;NC patients before initiation of treatment compared to after-treatment and healthy controls. No significant difference was observed between after-treatment patients and healthy controls. <i>TET3</i> gene promoter methylation was significantly correlated with 5-hydroxymethylcytosine levels (5-hmC) in H&amp;NC patients. <i>TET3</i> methylation can be used as a biomarker to assess response to treatment in H&amp;NC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blood Ten Eleven Translocase 3 Methylation Levels as a Marker to Assess Response to Treatment in Head and Neck Carcinoma Patients

  • 期刊论文

  • 发表日期：

    2025年10月25日

查看全文
  • Jyoti Kanwar Shekhawat,
  • Jyoti Sharma,
  • Bikram Choudhury,
  • Purvi Purohit,
  • Praveen Sharma,
  • Mithu Banerjee

摘要

Ten-eleven translocase (TET) enzymes are responsible for DNA demethylation reactions and play a key role in regulating the methylation balance in the body. TET expression instability may result in methylation alterations. We performed methylation specific-polymerase chain reaction to evaluate the TET3 promoter hypermethylation in the DNA isolated from the venous blood samples of head and carcinoma (H&NC) cases before initiation of treatment (n = 32) and after treatment (n = 30) and healthy controls (n = 32) in this study. TET3 promoter was found to be hypermethylated in H&NC patients before initiation of treatment compared to after-treatment and healthy controls. No significant difference was observed between after-treatment patients and healthy controls. TET3 gene promoter methylation was significantly correlated with 5-hydroxymethylcytosine levels (5-hmC) in H&NC patients. TET3 methylation can be used as a biomarker to assess response to treatment in H&NC patients.